Baillie Gifford & Co

Baillie Gifford & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baillie Gifford & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-82	Closed	-$8.49K	–	456
2022 Q4	$8.49K	Hold	82	–	–	﹤0.01%	423
2022 Q3	$7K	Hold	82	–	–	﹤0.01%	428
2022 Q2	$7K	Hold	82	–	–	﹤0.01%	435
2022 Q1	$6K	Hold	82	–	–	﹤0.01%	457
2021 Q4	$7K	Hold	82	–	–	﹤0.01%	464
2021 Q3	$6K	Hold	82	–	–	﹤0.01%	474
2021 Q2	$7K	Hold	82	–	–	﹤0.01%	448
2021 Q1	$6K	Buy	82 +8	+11%	+$654	﹤0.01%	427
2020 Q4	$6K	Buy	+74	New	+$5.87K	﹤0.01%	410
2013 Q4	–	Sell	-5,949	Closed	-$430K	–	209
2013 Q3	$430K	Hold	5,949	–	–	﹤0.01%	180
2013 Q2	$332K	Buy	+5,949	New	+$371K	﹤0.01%	155

Other funds holding BMRN

Primecap Management

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return